Clinical Trials Logo

Covid19 clinical trials

View clinical trials related to Covid19.

Filter by:

NCT ID: NCT05246137 Completed - COVID-19 Clinical Trials

A Phase III Trial to Assess the Safety and Immunogenicity of a HIPRA's Candidate Booster Vaccination Against COVID-19.

Start date: February 3, 2022
Phase: Phase 3
Study type: Interventional

This is a phase III clinical study to assess the safety, tolerability and immunogenicity of PHH-1V as a booster dose in healthy adult subjects vaccinated against COVID-19 with the Comirnaty, Spikevax, Vaxevria or Janssen vaccine.

NCT ID: NCT05246124 Completed - Anxiety Clinical Trials

The Effect of Demographic, Mental, and Physical Activity Profiles Towards Burnout in Frontline Healthcare Workers Facing COVID-19 Pandemics in Dr. Soetomo General Hospital Surabaya

Start date: May 25, 2020
Phase: N/A
Study type: Interventional

This was a randomized controlled trial study to measure the effect of intervention of Zumba dance towards psychological and biological markers in hospital residents managing COVID-19 patients

NCT ID: NCT05246072 Completed - COVID-19 Clinical Trials

Effect of Combined Use of Ivermectin and Colchicine in COVID-19 Patients

Start date: November 1, 2021
Phase: Phase 4
Study type: Interventional

The aim of this study will be to investigate the efficacy of use of combination of Ivermectin and colchicine on severity and outcome Of COVID 19 infection.

NCT ID: NCT05246059 Completed - Clinical trials for SARS CoV 2 Infection

Anosmia and Covid-19

COVANOS
Start date: June 3, 2020
Phase: N/A
Study type: Interventional

Our study aims to determine the prevalence of anosmia in patients SARS-Cov-2/Covid-19 infection (both by symptom reporting and smell testing), the efficacy of early olfactory training for the treatment of anosmia caused by infection and the long-term impact of smell dysfunction with a one-year follow-up.

NCT ID: NCT05244356 Completed - COVID-19 Clinical Trials

Health Communication to Influence COVID-19 Vaccination Intent and Message Propagation

CONVINCE
Start date: April 29, 2021
Phase: N/A
Study type: Interventional

This is a randomised controlled experiment in the form of a web based survey study which randomly exposes participants to different forms of public health messages, after which participants will be assessed on their intent to take up the COVID-19 vaccine, recommend the vaccine, and also willingness to propagate the exposed message.

NCT ID: NCT05244343 Completed - COVID-19 Clinical Trials

I VACCIN Hospitalization of COVID-19 Patients

Start date: January 25, 2022
Phase:
Study type: Observational

A REALLIFE evaluation of rate of hospitalized patients in Intensive Care Units and in medical Units of non -vaccinated patients vs vaccinated patients

NCT ID: NCT05244330 Completed - Clinical trials for SARS CoV 2 Infection

Effectiveness of COVID-19 Vaccines Against the SARS-COV-2 Delta (B.1.617.2)

FASTER
Start date: December 15, 2021
Phase:
Study type: Observational

Up to now, Corona Virus Disease 2019 (COVID-19) continues to spread rapidly around the world. From the beginning of the epidemic to the present, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has continuously evolved and mutated, producing transmissible and virulent variants. At present, the infection rate of Delta variant strains is still increasing globally. The epidemic strain of novel coronavirus infection in Xi 'an city is δ (B.1.617.2). SARS-CoV-2 Delta has more infectious, higher viral load and shorter incubation period than other SARS-COV-2 delta strains. Several studies have shown that the protective efficacy of vaccines against different SARS-COV-2 virus variants is different, and SARS-COV-2 viral load is closely related to transmission, clinical phenotype and prognosis of infected patients. According to the notice of Xi'an Municipal Health Commission, a total of 2,139 local confirmed cases were reported in Xi 'an on January 10,2022, and the proportion of severe cases was 2.36%, which was significantly lower than the 7% of nation since the second half of 2020. According to the preliminary investigation by the applicant's team, the severe illness rate in Xi'an has decreased significantly, which benefits from the active promotion of domestic vaccination, early intervention, and use of neutralizing antibodies. The purpose of this study is to analyze the effects of vaccination on nucleic acid turning negative, clinical characteristics and prognosis of patients infected with SARS-COV-2 delta, and to clarify the protective effects of vaccination, which is of great significance for the prevention and control of the SARS-COV-2 delta (B.1.617.2) in Xi' an.

NCT ID: NCT05240378 Completed - Cancer Clinical Trials

Mortality of Cancer Surgery During SARS CoV2 Pandemic

Start date: October 29, 2021
Phase:
Study type: Observational

The impact of cancer surgery during covid epidemic is not clear. The published reports show contradictory findings that extend from no change in mortality to increased mortality, further no data on exposure and outcome of health care worker is available. This study is designed to address the above questions

NCT ID: NCT05240183 Completed - Clinical trials for SARS-CoV2 Infection, COVID-19

Viral Dynamics of Omicron in Children

Start date: February 4, 2022
Phase:
Study type: Observational

SARS-CoV-2 transmission is dependent on multiple factors, which may be related to either host-virus interaction or the environment. While there have been several studies evaluation viral dynamics and transmission risk in adults, there is limited pediatric data available. The objective of this study is to characterize the period of communicability for children less than 19 years of age with SARS-CoV-2 infection with the Omicron variant.

NCT ID: NCT05239923 Completed - COVID-19 Pneumonia Clinical Trials

COVID19 Oral Vaccine Consisting of Bacillus Subtilis Spores

Start date: August 28, 2021
Phase: N/A
Study type: Interventional

This is a study trial to assess the effectiveness of the immune response stimulated by the genetically engineered Bacillus subtilis which express and display Spike protein of the SARS-COV2 on the spore coat.